BioSIM 抗甲型流感病毒 hemagglutinin/H

BioSIM 抗甲型流感病毒 hemagglutinin/HA 抗体 (那韦伏单抗)

产品货号：SIM0909-1mg

产品规格：1mg

CAS号：1443004-16-7

产品类型：二抗

供应商：InvivoCrown

产品概述

BioSIM 抗甲型流感病毒 hemagglutinin/HA 抗体 (那韦伏单抗) 是一种高品质的科研级生物类似抗体，专门针对甲型流感病毒的表面糖蛋白血凝素(HA)。该抗体作为那韦伏单抗的生物类似药，为科研人员提供了一种可靠的研究工具，用于探索流感病毒感染机制及相关治疗方案的开发。

产品特点与优势

• 高纯度：通过多步骤纯化过程制备，包括采用Protein A或G的色谱工艺，确保产品纯度
• 无动物成分生产：在无动物成分的设施中生产，仅使用体外的无蛋白细胞培养技术
• 人源化抗体：来源宿主为Human，具有较好的免疫相容性
• 特异性识别：针对甲型流感病毒的hemagglutinin/HA抗原，具有高度特异性

应用领域

该抗体适用于多种实验技术，可广泛应用于流感病毒感染相关的研究：

• ELISA：可用于检测和定量分析甲型流感病毒HA抗原
• FACS：适用于流式细胞术分析，用于细胞表面HA蛋白的检测
• Functional assay：可用于功能研究，评估抗体对病毒活性的影响
• Research in vivo：适用于体内研究，探索抗体在动物模型中的抗病毒效果

产品背景信息

那韦伏单抗是一种针对甲型流感病毒血凝素(HA)的单克隆抗体，血凝素作为流感病毒表面的主要糖蛋白，在病毒感染宿主细胞过程中扮演关键角色。该重组生物类似抗体通过先进的体外无蛋白细胞培养技术生产，避免了传统动物源抗体可能存在的批次差异问题，为科研人员提供了一种稳定可靠的研究工具。该产品特别适用于流感病毒感染机制研究、抗病毒药物开发以及疫苗效果评估等领域。

保存与储存建议

为确保产品的稳定性和活性，请遵循以下储存建议：

• 短期储存：对于1-2周内的使用需求，建议在4°C条件下保存
• 中期储存：最长12个月的储存周期，请在-20°C条件下保存
• 长期储存：对于超过12个月的长期储存，建议在-80°C条件下保存
• 重要提示：为避免抗体活性降低，请避免反复冻融

注：关于该抗体的免疫原信息，请参考产品说明书获取详细数据。

注意：以上信息可能随着产品优化升级等因素产生变动，具体信息请咨询亚科因公司。

BioSIM Anti-Influenza A Virus Hemagglutinin/HA Antibody (Nafivomab)

Product Number:SIM0909-1mg

Product Specification:1mg

CAS Number:1443004-16-7

Product Type:Secondary Antibody

Supplier:InvivoCrown

Product Overview

BioSIM Anti-Influenza A Virus Hemagglutinin/HA Antibody (Nafivomab) is a high-quality research-grade biosimilar antibody specifically targeting the surface glycoprotein hemagglutinin (HA) of influenza A virus. As a biosimilar of Nafivomab, this antibody provides researchers with a reliable research tool for exploring influenza virus infection mechanisms and the development of related therapeutic approaches.

Product Features and Advantages

• High Purity: Prepared through a multi-step purification process, including chromatography using Protein A or G, ensuring product purity
• Animal-Free Production: Produced in animal-free facilities using only protein-free in vitro cell culture technology
• Humanized Antibody: Derived from Human host with good immunocompatibility
• Specific Recognition: Highly specific against Influenza A virus hemagglutinin/HA antigen

Application Fields

This antibody is suitable for various experimental techniques and can be widely used in research related to influenza virus infection:

• ELISA: Can be used for detection and quantitative analysis of Influenza A virus HA antigen
• FACS: Suitable for flow cytometry analysis for detection of cell surface HA protein
• Functional assay: Can be used for functional studies to evaluate the effect of the antibody on viral activity
• Research in vivo: Suitable for in vivo research to explore the antiviral effects of the antibody in animal models

Product Background Information

Nafivomab is a monoclonal antibody targeting the hemagglutinin (HA) of Influenza A virus. As the major glycoprotein on the surface of influenza virus, hemagglutinin plays a key role in the process of viral infection of host cells. This recombinant biosimilar antibody is produced using advanced protein-free in vitro cell culture technology, avoiding potential batch-to-batch variations that may exist in traditional animal-derived antibodies, providing researchers with a stable and reliable research tool. This product is particularly suitable for research on influenza virus infection mechanisms, development of antiviral drugs, and evaluation of vaccine efficacy.

Storage Recommendations

To ensure product stability and activity, please follow the storage recommendations below:

• Short-term storage: For use within 1-2 weeks, storage at 4°C is recommended
• Medium-term storage: For storage periods up to 12 months, please store at -20°C
• Long-term storage: For long-term storage exceeding 12 months, storage at -80°C is recommended
• Important note: To prevent reduction of antibody activity, avoid repeated freeze-thaw cycles

Note: For immunogenicity information of this antibody, please refer to the product manual for detailed data.

Note: The above information may change due to factors such as product optimization and upgrades. For specific information, please consult Yacoin Biotechnology.